Small and long non-coding RNAs: Past, present, and future

LL Chen, VN Kim - Cell, 2024 - cell.com
Since the introduction of the central dogma of molecular biology in 1958, various RNA
species have been discovered. Messenger RNAs transmit genetic instructions from DNA to …

The promising role of new molecular biomarkers in prostate cancer: From coding and non-coding genes to artificial intelligence approaches

AP Alarcón-Zendejas, A Scavuzzo… - Prostate cancer and …, 2022 - nature.com
Background Risk stratification or progression in prostate cancer is performed with the
support of clinical-pathological data such as the sum of the Gleason score and serum levels …

The role of non-coding RNAs in glioma

A Goenka, DM Tiek, X Song, RP Iglesia, M Lu, B Hu… - Biomedicines, 2022 - mdpi.com
For decades, research in cancer biology has been focused on the protein-coding fraction of
the human genome. However, with the discovery of non-coding RNAs (ncRNAs), it has …

The metabolism-related lncRNA signature predicts the prognosis of breast cancer patients

X Ge, S Lei, P Wang, W Wang, W Wang - Scientific Reports, 2024 - nature.com
Long non-coding RNAs (lncRNAs) involved in metabolism are recognized as significant
factors in breast cancer (BC) progression. We constructed a novel prognostic signature for …

[HTML][HTML] Current advancements and future perspectives of long noncoding RNAs in lipid metabolism and signaling

J Duan, Z Huang, EC Nice, N **e, M Chen… - Journal of advanced …, 2023 - Elsevier
Background The investigation of lncRNAs has provided a novel perspective for elucidating
mechanisms underlying diverse physiological and pathological processes. Compelling …

Risk score= LncRNAs associated with doxorubicin metabolism can be used as molecular markers for immune microenvironment and immunotherapy in non-small cell …

Q Lin, M Zhang, Y Kong, Z Huang, Z Zou, Z **ong… - Heliyon, 2023 - cell.com
Doxorubicin is the most effective anthracycline chemotherapy drug in the treatment of
cancer, and it is an effective single agent in the treatment of non-small cell lung cancer …

Directional integration and pathway enrichment analysis for multi-omics data

M Slobodyanyuk, AT Bahcheli, ZP Klein… - Nature …, 2024 - nature.com
Omics techniques generate comprehensive profiles of biomolecules in cells and tissues.
However, a holistic understanding of underlying systems requires joint analyses of multiple …

Pan-cancer ion transport signature reveals functional regulators of glioblastoma aggression

AT Bahcheli, HK Min, M Bayati, H Zhao… - The EMBO …, 2024 - embopress.org
Ion channels, transporters, and other ion-flux controlling proteins, collectively comprising the
“ion permeome”, are common drug targets, however, their roles in cancer remain …

A CRISPR path to finding vulnerabilities and solving drug resistance: Targeting the diverse cancer landscape and its ecosystem

B McLean, A Istadi, T Clack, M Vankan… - Advanced …, 2022 - Wiley Online Library
Cancer is the second leading cause of death globally, with therapeutic resistance being a
major cause of treatment failure in the clinic. The dynamic signaling that occurs between …

Tumour mutations in long noncoding RNAs enhance cell fitness

R Esposito, A Lanzós, T Uroda… - Nature …, 2023 - nature.com
Long noncoding RNAs (lncRNAs) are linked to cancer via pathogenic changes in their
expression levels. Yet, it remains unclear whether lncRNAs can also impact tumour cell …